

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) ~~An A method for improving~~ insulin resistance improving in a ~~subject in need thereof comprising administering an effective amount of an~~ agent containing, as an active component, a C-terminal globular domain of adiponectin, ~~adiponectin, or a gene for the domain or adiponectin.~~

2. (Withdrawn) An insulin resistance improving agent containing, as active components, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin, and leptin or a gene for leptin.

3. (Currently Amended) ~~A method for treating type 2 diabetes in a subject in need thereof comprising administering an effective amount of a~~ therapeutic agent for type 2 diabetes containing, as an active component, a C-terminal globular domain of adiponectin, ~~adiponectin, or a gene for the domain or adiponectin.~~

4. (Withdrawn) A therapeutic agent for type 2 diabetes containing, as active components, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin, and leptin or a gene for leptin.

5. (Currently Amended) The ~~method~~ insulin resistance improving agent of claim 1, wherein said agent further comprises a pharmacologically acceptable carrier.

6. (Currently Amended) The ~~method~~ insulin resistance improving agent of claim 5,

wherein said pharmacologically acceptable carrier is selected from the group consisting of distilled water, a solubilizer, a stabilizer, an emulsifier, and a buffer.

7. – 8. (Canceled)

9. (Currently Amended) The ~~method~~ therapeutic agent for type 2 diabetes of claim 3, wherein said therapeutic agent further comprises a pharmacologically acceptable carrier.

10. (Currently Amended) The ~~method~~ therapeutic agent for type 2 diabetes of claim 9, wherein said pharmacologically acceptable carrier is selected from the group consisting of distilled water, a solubilizer, a stabilizer, an emulsifier, and a buffer.

11. – 12. (Canceled)

13. (New) The insulin resistance improving agent of claim 1, wherein said C-terminal globular domain of adiponectin encompasses amino acid residues 114 to 239 of SEQ ID NO: 1.

14. (New) The insulin resistance improving agent of claim 1, wherein said C-terminal globular domain of adiponectin encompasses amino acid residues 111 to 242 of SEQ ID NO: 1.

15. (New) The therapeutic agent for type 2 diabetes of claim 3, wherein said C-terminal globular domain of adiponectin encompasses amino acid residues 114 to 239 of SEQ

ID NO: 1.

16. (New) The therapeutic agent for type 2 diabetes of claim 3, wherein said C-terminal globular domain of adiponectin encompasses amino acid residues 111 to 242 of SEQ

ID NO: 1.